Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ijid.2020.08.047 http://scihub22266oqcxt.onion/10.1016/j.ijid.2020.08.047 32829044!7441042!32829044     free     free     free       Int+J+Infect+Dis 2020 ; 100 (?): 283-285 Nephropedia Template TP {{tp|p=32829044|t=2020. Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition |pdf=|usr=}}{{32829044}} gab.com Text Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition JO: Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32829044 #FOAvip The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak is rising globally. However, clinically effective antiviral treatments are not established. Favipiravir may prevent pneumonia and acute respiratory distress syndrome aggravation. We describe SARS-CoV-2-positive patients, two of whom were in a critical condition and one of whom was in a severe condition, who were administered favipiravir for their deteriorating conditions and cured. Twit Text FOAVip Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition ????Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32829044 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32829044 #FOAvip English Wikipedia <ref>{{Cite pmid|32829044}}</ref> Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition #MMPMID32829044 Takahashi H; Iwasaki Y; Watanabe T; Ichinose N; Okada Y; Oiwa A; Kobayashi T; Moriya M; Oda T Int J Infect Dis 2020[Nov]; 100 (?): 283-285 PMID32829044show ga The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak is rising globally. However, clinically effective antiviral treatments are not established. Favipiravir may prevent pneumonia and acute respiratory distress syndrome aggravation. We describe SARS-CoV-2-positive patients, two of whom were in a critical condition and one of whom was in a severe condition, who were administered favipiravir for their deteriorating conditions and cured. |Amides/*therapeutic use[MESH] |Antiviral Agents/*therapeutic use[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Pyrazines/*therapeutic use[MESH] |SARS-CoV-2[MESH]Case studies of SARS-CoV-2 treated with favipiravir among patients in (epmc).pdf DeepDyve Pubget Overpricing